This study evaluates a monoclonal antibody targeting pyroglutamate-modified Aβ (pGlu3-Aβ), demonstrating reduced amyloid plaque load, enhanced microglial engagement, and preserved synaptic integrity in Alzheimer’s disease models.
pGlu3-Aβ immunotherapy reduces plaque load, activates microglia, and protects synapses, suggesting therapeutic potential in AD.
Transgenic hAPP mouse crossed with genOway’s Cx3cr1-CreERT2-tdTomato line for microglial lineage tracing and activation analysis.
Alzheimer’s disease, Neuroinflammation, Microglial activation, Immunotherapy
Humanized APP model, Inducible CreERT2, tdTomato reporter, Microglial tracing, Knockin at endogenous Cx3cr1 locus
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
